Actively Recruiting
Dupilumab Effects Against Aeroallergen Challenge
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-03-06
88
Participants Needed
2
Research Sites
239 weeks
Total Duration
On this page
Sponsors
T
The University of Texas Health Science Center at San Antonio
Lead Sponsor
N
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
CONDITIONS
Official Title
Dupilumab Effects Against Aeroallergen Challenge
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and provide signed informed consent
- Male or female aged 18 to 65 years at screening
- Symptoms consistent with perennial nasal allergy for at least 2 years prior to screening
- Positive skin prick test to D. pteronyssinus within 24 months of screening (wheal diameter at least 5 mm larger than control)
- Asthma with documented FEV1 reversibility of at least 10% within 18 months of screening
- Negative SARS-CoV-2 test if symptoms suggestive of COVID-19 before each HDM exposure
- Women of childbearing potential must have negative pregnancy tests and agree to acceptable birth control methods during study and 2 months prior
- Never smoked or ex-smoker with less than 20 pack-years and no tobacco use in past year
You will not qualify if you...
- Chronic lung disease other than asthma
- Atopic dermatitis
- Ocular disease not linked to allergic rhinoconjunctivitis
- Home oxygen requirement
- History of rebound nasal congestion or severe nasal conditions
- FEV1 less than 70% predicted at screening
- Unable or unwilling to withhold intranasal steroids or asthma medications as required
- Unable or unwilling to avoid prohibited medications during screening and exposure visits
- Use of systemic glucocorticosteroids within 1 month prior to screening
- Use of JAK-1 inhibitors within 3 months prior to screening
- Known allergy to dupilumab or its ingredients
- Ongoing helminth infection
- Recent or planned live vaccine within 30 days of screening
- Pregnant or nursing
- History of keratoconjunctivitis sicca
- Indoor pet exposure causing symptoms
- Allergen immunotherapy within 12 months of screening
- Use of biologics other than certain anti-obesity or diabetes medications within 12 months
- Participation in investigational drug trial within 30 days
- Any other medical conditions or findings that increase risk or interfere with study compliance according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Biogenics Research Chamber
San Antonio, Texas, United States, 78229
Actively Recruiting
2
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
S
Sunil K Ahuja, MD
CONTACT
A
Alisha Smith, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here